A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Guselkumab Dose 1
DRUG: Guselkumab Dose 2
DRUG: Guselkumab Dose 3
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC